# Transchem (NSE: TRANSCHEM) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/TRANSCHEM · Pivot · prices to 19 Oct 2026

With a market capitalisation of ₹391 Cr, it ranks 1913th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Shell Companies.

Its return on equity was 5.1% in FY26. Promoters held 56.45% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹391 Cr |
| ROE | 5.1% (FY26) |
| ROCE | 6.7% (FY26) |
| Debt to equity | 0 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | — | — | ₹2 Cr | +186.3% | ₹1.71 |
| Q3 FY26 | — | — | ₹1 Cr | −61.9% | ₹0.43 |
| Q2 FY26 | — | — | ₹1 Cr | −52.8% | ₹0.56 |
| Q1 FY26 | — | — | ₹1 Cr | −40.4% | ₹0.81 |
| Q4 FY25 | ₹2 Cr | +490.2% | ₹1 Cr | −41.6% | ₹0.60 |
| Q3 FY25 | ₹0 Cr | — | ₹1 Cr | +21.9% | ₹1.13 |
| Q2 FY25 | — | — | ₹1 Cr | +48.5% | ₹1.18 |
| Q1 FY25 | — | — | ₹2 Cr | +95.3% | ₹1.36 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY26 | ₹0 Cr | ₹4 Cr |
| FY25 | ₹3 Cr | ₹5 Cr |
| FY24 | ₹0 Cr | ₹4 Cr |
| FY23 | ₹0 Cr | ₹1 Cr |
| FY22 | ₹0 Cr | ₹3 Cr |
| FY21 | ₹22 Cr | ₹24 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 56.45%
- Foreign institutions: 0.03%
- Domestic institutions: 0.01%
- Non-institutions: 43.52%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Albert David](https://app.pivotnow.in/stock/ALBERTDAVD) | ₹795.00 | ₹454 Cr | — | — |
| [Asarfi Hospital](https://app.pivotnow.in/stock/ASARFI) | — | ₹446 Cr | — | — |
| [Jenburkt Pharma](https://app.pivotnow.in/stock/JENBURPH) | ₹905.20 | ₹399 Cr | 11.5 | — |
| [Aptus Pharma](https://app.pivotnow.in/stock/APPL) | — | ₹377 Cr | — | — |
| [Medicamen Biotech](https://app.pivotnow.in/stock/MEDICAMEQ) | ₹273.35 | ₹371 Cr | 37.9 | — |
| [Astal  Lab](https://app.pivotnow.in/stock/ASTALLTD) | — | ₹358 Cr | — | — |

## Questions and answers

### What is the market cap of Transchem?

Transchem's market capitalisation is ₹391 Cr (₹391 Cr) at the 19 Oct 2026 close, ranking 1913th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Transchem?

Return on equity was 5.1% in FY26 and return on capital employed was 6.7% in FY26 (standalone figures).

### Is Transchem a debt-free company?

Transchem is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### What is the shareholding pattern of Transchem?

As of 30 Jun 2026: promoters 56.45%, foreign institutions 0.03%, domestic institutions 0.01%, non-institutions 43.52%.

### Who are Transchem's competitors?

The listed Pharma & Healthcare companies closest to Transchem by market cap are Albert David, Asarfi Hospital, Jenburkt Pharma, Aptus Pharma, Medicamen Biotech and Astal  Lab.

### Is Transchem a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Transchem's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on TRANSCHEM against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.